Conference Coverage

Comparison of Low-Dose Platinum vs High-Dose Platinum vs Cetuximab and Intensity-Modulated Radiation Therapy in Advanced Head and Neck Cancers

Giri S, Kankamedhala M, Suggs JM.

Abstract 7: 2014 AVAHO Meeting


 

Purpose: High-dose cisplatin is standard in head and neck cancers. Recently, weekly low-dose platinum alone or with cetuximab has been used. All patients received 70 Gy standard fraction intensity-modulated radiation therapy. We are comparing the former used at the VAMC with the latter regimens used in the department of Oncology at the University of Mississippi. We will present the toxicity, response, patterns of failure, and survival by the use of the different types of chemotherapy.

Recommended Reading

Second Primary Tumors and Nasopharyngeal Carcinoma
AVAHO
Chemotherapy for Advanced Head and Neck Cancer
AVAHO
Guidelines for Thyroid Nodule Evaluation
AVAHO
Eruptive Collagenomas, Suprasellar Meningioma, and Elevated Prolactin in a Patient With a History of Papillary Thyroid Carcinoma
AVAHO
Cisplatin Is Associated With Prolonged Progression-Free Survival Compared With Cetuximab Among Veteran Patients With Stage 3 And 4 Head and Neck Cancer
AVAHO
Incorporation of Palliative Care With Chemotherapy and Radiation in Patients Treated for Head and Neck Cancer
AVAHO
Incidence of Second Primary Malignancies in Patients Treated for Thyroid Cancer: A Review of 51 Cases
AVAHO